Bone marrow stromal cells were found to up-regulate G6PD expression via interleukin-6 (IL-6) secretion, and targeting G6PD either pharmacologically or genetically could inhibit prostate cancer proliferation, migration, mesenchymal phenotype, and sensitivity to chemotherapy. This evidence concerns the gene IL6 and Familial prostate cancer.